Roche Holding AG Stock London S.E.

Equities

0TDF

US7711951043

Pharmaceuticals

Market Closed - London S.E. 09:31:49 2024-06-12 am EDT 5-day change 1st Jan Change
34.01 USD +7.19% Intraday chart for Roche Holding AG -2.10% -5.26%
Sales 2024 * 60.46B 67.4B Sales 2025 * 63.88B 71.22B Capitalization 204B 227B
Net income 2024 * 13.43B 14.98B Net income 2025 * 14.86B 16.57B EV / Sales 2024 * 3.61 x
Net Debt 2024 * 14.25B 15.89B Net Debt 2025 * 9.13B 10.18B EV / Sales 2025 * 3.33 x
P/E ratio 2024 *
14.7 x
P/E ratio 2025 *
13.4 x
Employees 103,605
Yield 2024 *
3.88%
Yield 2025 *
3.98%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day+7.19%
1 week-2.10%
Current month-1.93%
1 month+1.86%
3 months+9.99%
6 months-8.06%
Current year-5.26%
More quotes
1 week
33.99
Extreme 33.99
34.09
1 month
33.99
Extreme 33.99
35.62
Current year
29.27
Extreme 29.27
37.27
1 year
29.27
Extreme 29.27
39.62
3 years
29.27
Extreme 29.27
53.30
5 years
29.27
Extreme 29.27
53.72
10 years
27.60
Extreme 27.6
53.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 66 95-12-31
More insiders
Date Price Change Volume
24-07-08 33.99 -0.38% 0

Delayed Quote London S.E., June 12, 2024 at 09:31 am EDT

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
252.1 CHF
Average target price
274 CHF
Spread / Average Target
+8.69%
Consensus